Faculty

Institution

Unit

Venue

Amin, Hesham M

Assistant Professor Tenure Track Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Pathology

Department Of Hematopathology

Department Of Pathology And Genomic Medicine

Department Of Surgical Pathology

The University of Texas MD Anderson Cancer Center

Hesham M. Amin is an Assistant Professor (Tenure Track) at The University of Texas MD Anderson Cancer Center. His research focuses on hepatocellular carcinoma (HCC), specifically investigating prognostic and therapeutic biomarkers, including the growth hormone pathway, insulin-like growth factor 1, and circulating fibroblast growth factor 21. His recent work has identified high-impact susceptibility loci for HCC through genome-wide association studies and evaluated circulating tumor DNA as a response biomarker to nivolumab therapy. He has also contributed to measurable residual disease detection in acute myeloid leukemia using error-corrected next-generation sequencing. His publications appear in journals such as Hepatology, Journal of Gastrointestinal Surgery, and Advances in Radiation Oncology, reflecting his translational focus on tumor biology, pathology, and precision oncology.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Amin, Hesham M

The University of Texas MD Anderson Cancer Center

Assistant Professor Tenure Track Professor

You can click a keyword to filter the displayed items

oncology cancer research pathology tumor biology cell biology oncogenes immunology leukemia hematology pharmacology medicinal research lymphoid neoplasia cancer cells cancer biology hematological malignancies hepatocellular carcinoma liver cancer hepatology molecular cancer cell signaling cancer immunotherapy cancer care cancer treatment therapeutic targets surgical oncology cancer discovery cancer genetics cell death cellular therapy tumor suppressors tumor targeting anti-cancer agents myeloid neoplasia apoptosis liver physiology clinical evidence advanced solid tumors histopathology vascular biology cell regulation pharmacotherapy receptor tyrosine kinases cancer growth signaling pathways liver disease adult t-cell leukemia-lymphoma cancer risk enzyme inhibition molecular cell biology gastrointestinal oncology novel therapies prognostic biomarkers mantle cell lymphoma advanced hepatocellular carcinoma immune checkpoint inhibitors cytokines cancer genomics myelodysplastic syndrome prognostic significance lymphatic disease cellular immune responses molecular profiling prognostic biomarker acute myeloid leukemia cancer immunosurveillance 3d modeling 3d bioprinting gene regulation novel oncogene differential expression signal transducer united states growth hormone receptor tumor dna postsplenectomy cytomegaloviral mononucleosis constitutive nf-kb activation surgery internal medicine metastasis translational research gynecologic oncology oral pathology neuro-oncology anesthesiology anatomical pathology gynecology translational medicine medicine patient safety haematopoiesis clinical biochemistry blood purification breast cancer tumor microenvironment critical care jama oncology health sciences individualized medicine medical history urology sarcoma surgical pathology lung cancer cancer letter carcinogenesis thoracic oncology radiation oncology free radical biology mesothelioma clinical research clinical investigation oxidative stress experimental medicine molecular medicine

Notable Scholarly Works

Notable Federal Grants

Collaborators

Growth Hormone Pathway as a Prognostic and Therapeutic Biomarker in Patients With Unresectable Hepatocellular Carcinoma Treated With Radiation Therapy. Advances in Radiation Oncology (2026)

hepatologypathologymolecular cancerliver canceroncologyhepatocellular carcinomaradiation oncologyradiationradiation therapyradiation biologygrowth hormone pathwaycancer cellstherapeutic biomarker

1252 Npm1 Mutation Detection Using Ultrasensitive Error-Corrected Ngs Improves Identification of Measurable Residual Acute Myeloid Leukemia. Laboratory Investigation (2025)

pathologybiostatisticsmolecular diagnosticsmolecular medicinecancer researchoncogeneshematological malignanciesleukemiamyeloid neoplasiahematology

Circulating Fibroblast Growth Factor 21 (Fgf21) as a Prognostic and Diagnostic Biomarker in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma (2025)

hepatologypathologymolecular canceroncogenescancer researchliver cancerbiomarkershepatocellular carcinomafibroblast growth factorscell biologydiagnostic biomarker

Evaluating the Role of Preoperative Serum Insulin-Like Growth Factor 1 as a Predictor of Survival and Recurrence for Patients With Resectable Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery (2025)

hepatologypathologyliver cancerliver physiologyoncologyhepatocellular carcinomaradiation oncologysurgical oncologyresectable hepatocellular carcinoma

Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma. Journal of Immunotherapy and Precision Oncology (2024)

Shadi ChamseddineBetul Gok YavuzYehia I. MohamedSunyoung S. LeeJames C. YaoZishuo Ian HuMichael LaPelusaLianchun XiaoRyan SunJeffrey S. MorrisRikita I. HatiaManal HassanDan G. DudaMaria DiabAmr MohamedAhmed NassarHesham M. AminAhmed Omar Kaseb

prognostic biomarkeroncologyhepatocellular carcinomaimmunotherapyimmunologyprognostic biomarkers

Circulating Tumor Dna (Ctdna) as a Biomarker of Response to Therapy in Advanced Hepatocellular Carcinoma Treated With Nivolumab. Cancer Biomarkers (2024)

Yehia I. MohamedSunyoung S. LeeTarik DemirShadi ChamseddineZishuo Ian HuLianchun XiaoKhaled ElsayesJeffrey S. MorrisRobert A. WolffRikita HiatiaAliya QayyumAsif RashidDan G. DudaJames C. YaoMichael LaPelusaEugene J. KoayArmeen MahvashAhmed Al AzzamEcaterina E. DumbravaManal HassanHesham M. AminAhmed Omar Kaseb

pathologytumor targetingadvanced hepatocellular carcinomatumor dnabiomarker (medicine)cancer biologymolecular cancercancer researchtumor biologymolecular diagnosticscancer treatmentoncologyhepatocellular carcinomaoncogenestumor microenvironmentbiomarkerscancer discoveryradiation oncologymolecular biologymedicinal research

From Mitochondria to Tumor Suppression: Acat1'S Crucial Role in Gastric Cancer. Frontiers in Immunology (2024)

cancer biologycell deathimmunologycarcinogenesis

Genome-Wide Association Study Identifies High-Impact Susceptibility Loci for Hcc in North America. Hepatology (2024)

Manal M. HassanDonghui LiYounghun HanJinyoung ByunRikita I. HatiaErping LongJiyeon ChoiRobin Kate KelleySean P. ClearyAnna S. LokPaige BracciJennifer B. PermuthRoxana BucurJian-Min YuanAmit G. SingalPrasun K. JalalR. Mark GhobrialRegina M. SantellaYuko KonoDimpy P. ShahMindie H. NguyenGeoffrey LiuNeehar D. ParikhRichard KimHui-Chen WuHashem El-SeragPing ChangYanan LiYun Shin ChunSunyoung S. LeeJian GuErnest HawkRyan SunChad HuffAsif RashidHesham M. AminLaura BerettaRobert A. WolffSamuel O. AntwiYehuda PattLu-Yu HwangAlison P. KleinKaren ZhangMikayla A. SchmidtDonna L. WhiteJohn A. GossSaira A. KhaderiJorge A. MarreroFrancisco G. CigarroaPankil K. ShahAhmed O. KasebLewis R. RobertsChristopher I. Amos

geneticshepatologyhuman geneticshigh-impact susceptibility locigenome-wide association studiesgenomicshematologynorth americaepidemiology

Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients With Advanced Hepatocellular Carcinoma.. Journal of Clinical Oncology (2024)

hepatologypathologyadvanced hepatocellular carcinomamolecular cancerprognostic biomarkeroncogenesliver canceroncologyhepatocellular carcinomaradiation oncologyplasma growth hormone

Severe Febrile Neutropenia and Pancytopenia in a Patient With Advanced Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab: A Case Report. Journal of Gastrointestinal Oncology (2024)

Shadi ChamseddineMichael LaPelusaKristen CarterVan NguyenYehia I MohamedYara SakrCristhiam M Rojas-HernandezRikita I HatiaManal HassanJohn A GossKhaled M ElsayesAsif RashidRyan SunHop Sanderson Tran CaoHesham M AminAhmed O Kaseb

pathologyadvanced hepatocellular carcinomasurgical oncologygynecologic oncologyclinical microbiologyhepatologycancer researchliver cancerliver diseaseinfectious diseasesoncologygastroenterologyhepatocellular carcinomacancer caregastrointestinal oncologycancer immunotherapyoncogenesfebrile neutropeniaradiation oncologyhepatobiliary tumors

1
2
3
4
5
19
10 / page

Amin, Hesham M

Assistant Professor Tenure Track Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Pathology

Department Of Hematopathology

Department Of Pathology And Genomic Medicine

Department Of Surgical Pathology

The University of Texas MD Anderson Cancer Center

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Amin, Hesham M

The University of Texas MD Anderson Cancer Center

Assistant Professor Tenure Track Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Growth Hormone Pathway as a Prognostic and Therapeutic Biomarker in Patients With Unresectable Hepatocellular Carcinoma Treated With Radiation Therapy. Advances in Radiation Oncology (2026)

hepatologypathologymolecular cancerliver canceroncologyhepatocellular carcinomaradiation oncologyradiationradiation therapyradiation biologygrowth hormone pathwaycancer cellstherapeutic biomarker

1252 Npm1 Mutation Detection Using Ultrasensitive Error-Corrected Ngs Improves Identification of Measurable Residual Acute Myeloid Leukemia. Laboratory Investigation (2025)

pathologybiostatisticsmolecular diagnosticsmolecular medicinecancer researchoncogeneshematological malignanciesleukemiamyeloid neoplasiahematology

Circulating Fibroblast Growth Factor 21 (Fgf21) as a Prognostic and Diagnostic Biomarker in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma (2025)

hepatologypathologymolecular canceroncogenescancer researchliver cancerbiomarkershepatocellular carcinomafibroblast growth factorscell biologydiagnostic biomarker

hepatologypathologyliver cancerliver physiologyoncologyhepatocellular carcinomaradiation oncologysurgical oncologyresectable hepatocellular carcinoma

Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma. Journal of Immunotherapy and Precision Oncology (2024)

prognostic biomarkeroncologyhepatocellular carcinomaimmunotherapyimmunologyprognostic biomarkers

Circulating Tumor Dna (Ctdna) as a Biomarker of Response to Therapy in Advanced Hepatocellular Carcinoma Treated With Nivolumab. Cancer Biomarkers (2024)

From Mitochondria to Tumor Suppression: Acat1'S Crucial Role in Gastric Cancer. Frontiers in Immunology (2024)

cancer biologycell deathimmunologycarcinogenesis

Genome-Wide Association Study Identifies High-Impact Susceptibility Loci for Hcc in North America. Hepatology (2024)

geneticshepatologyhuman geneticshigh-impact susceptibility locigenome-wide association studiesgenomicshematologynorth americaepidemiology

Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients With Advanced Hepatocellular Carcinoma.. Journal of Clinical Oncology (2024)

hepatologypathologyadvanced hepatocellular carcinomamolecular cancerprognostic biomarkeroncogenesliver canceroncologyhepatocellular carcinomaradiation oncologyplasma growth hormone

Severe Febrile Neutropenia and Pancytopenia in a Patient With Advanced Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab: A Case Report. Journal of Gastrointestinal Oncology (2024)

1
2
3
4
5
19
10 / page